Pristinamycin (Synonyms: 棱镜霉素; Pristinamycine)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Pristinamycin  (Synonyms: 棱镜霉素; Pristinamycine) 纯度: 99.63%

Pristinamycin 是一种具有口服活性的链霉素样的抗生素，产生于 Streptomyces pristinaespiralis，Pristinamycin 由两种化学上不相关的成分组成：Pristinamycin I (PI) 和 Pristinamycin II (PII)。Pristinamycin 对多种抗生素耐药病原菌，特别是革兰氏阳性菌，包括耐甲氧西林金黄色葡萄球菌 (MRSA)、万古霉素耐药金黄色葡萄球菌 (VRSA) 和粪肠球菌 (VREF) 具有高度的活性。

Pristinamycin (Synonyms: 棱镜霉素; Pristinamycine)

Pristinamycin Chemical Structure

CAS No. : 270076-60-3

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥4000 In-stock
25 mg ￥8500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Pristinamycin 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Natural Product Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Macrocyclic Compound Library
  • Antibacterial Compound Library
  • Orally Active Compound Library
  • Antibiotics Library
  • Microbial Metabolite Library
  • Anti-Drug-Resistant Compound Library

•同靶点产品:

•同靶点蛋白产品:

生物活性

Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF)[1].

体外研究
(In Vitro)

In-vitro studies show pristinamycin to inhibit Staphylococci and Streptococci, including Erythromycin highly-resistant organisms, at a concentration of less than or equal to 0.78 mg/l[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Pristinamycin 相关抗体:
体内研究
(In Vivo)

To study Pristinamycin activity in vivo, mice infected IP with C. psittaci. Mortality in the control group was 70%. Three groups of mice received 25 mg/kg, 50 mg/kg and 100 mg/kg Pristinamycin respectively. The antibiotic was active in the 100 mg/kg dosage which is the therapeutic dosage[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

1392.55

Formula

C73H89N11O17
CAS 号

270076-60-3
性状

固体

颜色

Light yellow to yellow

中文名称

棱镜霉素
结构分类
  • Antibiotics
  • Disease Research
  • Antibacterial
  • Antibiotics
  • Macrolide Antibiotics
初始来源
  • 微生物

streptogramin
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO 中的溶解度 : 100 mg/mL (71.81 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.7181 mL 3.5905 mL 7.1811 mL
5 mM 0.1436 mL 0.7181 mL 1.4362 mL
10 mM 0.0718 mL 0.3591 mL 0.7181 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

=

浓度

×

体积

×

分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×

体积 (start)

V1

=

浓度 (final)

C2

×

体积 (final)

V2

扫码获得
动物溶解方案

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果
工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.63%

Data Sheet (539 KB) SDS (251 KB)

COA (180 KB) LCMS (109 KB)

产品使用指南 (1538 KB)

参考文献

  • [1]. Meng J, et al. Improvement of pristinamycin I (PI) production in Streptomyces pristinaespiralis by metabolic engineering approaches. Synth Syst Biotechnol. 2017;2(2):130-136. Published 2017 Jun 8.  [Content Brief]

    [2]. Maskell JP, et al. Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin. Infection. 1988;16(6):365-370.  [Content Brief]

    [3]. Orfila J, Haider F. Action de la pristinamycine sur les Chlamydia [Action of pristinamycin on Chlamydia]. Pathol Biol (Paris). 1984;32(5):443-445.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务